(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 7.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.
United Therapeutics's revenue in 2023 is $2,204,300,000.On average, 7 Wall Street analysts forecast UTHR's revenue for 2023 to be $106,405,824,987, with the lowest UTHR revenue forecast at $104,023,155,430, and the highest UTHR revenue forecast at $108,513,394,005. On average, 7 Wall Street analysts forecast UTHR's revenue for 2024 to be $117,242,972,320, with the lowest UTHR revenue forecast at $113,040,099,615, and the highest UTHR revenue forecast at $129,406,749,010.
In 2025, UTHR is forecast to generate $126,883,333,617 in revenue, with the lowest revenue forecast at $114,193,510,558 and the highest revenue forecast at $146,813,648,756.